HOME > TOP STORIES
TOP STORIES
-
BUSINESS Lilly Japan Chief Sees Continued Diabetes Investment as Key to Remaining in Top 10
June 22, 2020
-
ACADEMIA Nobel Laureate Honjo Sues Ono over Opdivo Royalties, Demands 22.6 Billion Yen
June 22, 2020
-
REGULATORY MHLW Delays Chuikyo Discussion Timeline for Off-Year Price Survey, Drops June-End Goal
June 22, 2020
-
BUSINESS Keytruda Logs 64% Growth, Tops FY2019 Drug Ranking: Jiho Tally
June 19, 2020
-
BUSINESS Ono President Confident of Validity of Company’s Argument on Opdivo Royalties
June 19, 2020
-
REGULATORY Chuikyo Doctor Reps Nix Drug Price Survey Discussion, Say It Should Only Come after Govt’s Go/No-Go Decision
June 18, 2020
-
BUSINESS 10 Foreign Makers in Japan Grow Above Market with 5.5% Sales Rise in 2019
June 17, 2020
-
REGULATORY MHLW to Propose Two-Third Sampling Rate for Wholesaler Survey for Off-Year Drug Re-Pricing; Go/No-Go Debate to Continue
June 16, 2020
-
BUSINESS 26 Japan Drug Makers Generate 56.4% of Sales Overseas in FY2019, Shire Buy Gives Boost: Tally
June 15, 2020
-
ORGANIZATION New Special Rule for “Indication Change” Re-Pricing Significantly Lacks Predictability: FPMAJ
June 12, 2020
-
REGULATORY Industry Says There’s No Way Off-Year Drug Price Survey Can Be Done; Chuikyo Healthcare Reps Agree but Payers Don’t
June 11, 2020
-
ORGANIZATION Daiichi Sankyo CEO Manabe Set to Gain Lobbying Experience as FPMAJ Vice Chair, Chairman Seat Eyed for 2021
June 10, 2020
-
REGULATORY Stable Supply Debate Set to Heat Up in Japan, Scientific Societies to Select Key Drugs by June-End
June 9, 2020
-
BUSINESS Big 3 Generic Firms Log 5.9% Sales Increase in FY2019, with Contraction in Overseas Business: Jiho Tally
June 9, 2020
-
ORGANIZATION Japan Pharma Trade Group Nudges Govt to Postpone Off-Year Re-Pricing
June 8, 2020
-
ACADEMIA Remdesivir Not Used as Severe Cases Decreased, Avigan/Alvesco Given to Several Dozen Patients: TMDU Hospital
June 5, 2020
-
BUSINESS Kyowa Kirin Looks to Make Crysvita 1st In-House Blockbuster, Sees 100 Billion Yen Target “Not Unachievable”
June 5, 2020
-
ORGANIZATION API/Intermediate Imports from India Still Stalled, Traders’ Group Calls for Govt Schemes
June 4, 2020
-
BUSINESS Kyowa Hakko Bio’s GMP Breach Triggers Shipment Curbs, Stockouts at Astellas, Kowa; Impact Could Reverberate Further
June 3, 2020
-
BUSINESS 15 Drug Makers See 3.6% Negative Growth in Japan in FY2020 as Re-Pricing, Generic Entries Weigh: Jiho Tally
June 2, 2020
ページ
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…